Raloxifene covalently bonded to titanium implants by interfacing with (3-aminopropyl)-triethoxysilane affects osteoblast-like cell gene expression

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 4, 2006, Pages 905-914

  Bambini, F ^a   Greci, L ^a   Meme L ^a   Santarelli, A ^a   Carinci, F ^b   Pezzetti, F ^b   Procaccini, M ^a   Lo Muzio, Lorenzo ^c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

(3 aminopropyl) triethoxysilane; cDNA microarrays; Covalent bond; Osteoblast; Raloxifene; Titanium

Indexed keywords

3 AMINOPROPYLTRIETHOXYSILANE; RALOXIFENE; TITANIUM;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DNA MICROARRAY; DRUG ANALYSIS; DRUG BINDING; DRUG COATING; DRUG MECHANISM; DRUG SYNTHESIS; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMPLANT; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

EID: 33846496809     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200601900420     Document Type: Article

References (20)

1. Kasemo B. and J. Gold. 1999. Implant surfaces and interface processes. Adv. Dent. Res. 13:8.
2. Osborn J.F. and H. Newsley. 1980. Dynamic aspects of the implant-bone interface. In: Dental Implants Materials and System. G. Heimke, ed. Hamser Verlag, Munchen, p. 11.
3. Nanci A., J.D. Wuest, L. Peru, P. Brunet, V. Sharma, S. Zalzal and M.D. McKee. 1998. Chemical modification of titanium surfaces for covalent attachment of biological molecules. J. Biomed. Mater. Res. 40:324.
4. Jones C.D., M.G. Jevnikar, A.J. Pike, M.K. Peters, L.J. Black, A.R Thompson, J.F. Falcone and J.A. Clemens. 1984. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphen yl)benzo[b]thien-3-yl][4-[2- (1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY1 56758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27:1057.
5. Richelson L.S., H.W. Wahner, L.J. Melton 3rd and B.L. Riggs. 1984. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N. Engl. J. Med. 311:1273.
6. Lindsay R., D.M. Hart, J.M. Aitken, E.B. MacDonald, J.B. Anderson and A.C. Clarke. 1976. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038.
7. Draper M.W., D.E. Flowers, W.J. Huster, J.A. Neild, K.D. Harper and C. Arnaud. 1996. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11:835.
8. Black L.J., C.D. Jones and J.F. Falcone. 1983. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32:1031.
9. Kumar V., S. Green, G. Stack, M. Berry, J.R. Jin and P. Chambon. 1987. Functional domains of the human estrogen receptor. Cell 51:941.
10. Sato M. et al. 1994. Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femorae of ovx rats. J. Bone Miner. Res. 9:715.
11. Evans G., H.U. Bryant, D. Magee, M. Sato and R.T. Turner. 1994. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283.
12. March J. 1985. Advanced organic chemistry, third edition, ed. John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore, p. 1.
13. Shi Y. and J. Massague. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685.
14. Nohe A., E. Keating, T.M. Underhill, P. Knaus and N.O. Petersen. 2003. Effect of the distribution and clustering of the type I A BMP receptor (ALK3) with the type II BMP receptor on the activation of signalling pathways. J. Cell Sci. 116:3277.
15. Harumiva S., M.A. Gibson and Y. Koshihara. 2002. Antisense suppression of collagen VI synthesis results in reduced expression of collagen I in normal human osteoblast-like cells. Biosci. Biotechnol. Biochem. 66:2743.
16. Ishibashi H., S. Harumiya and Y. Koshihara. 1999. Involvement of type VI collagen in interleukin-4-induced mineralization by human osteoblast-like cells in vitro. Biochim. Biophys Acta 1472:153.
17. Van Aelst L. and C. D'Souza-Schorey. 1997. Rho GTPases and signaling networks. Genes Dev. 11:2295.
18. Pruitt K. and C.J. Der. 2001. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:1.
19. Chaplet M., C. Detry, C. Deroanne, L.W. Fisher, V. Castronovo and A. Bellahcene. 2004. Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem. J. 384:591.
20. Radeff J.M., Z. Nagy and P.H. Stern. 2004. Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. J. Bone Miner. Res. 19:1882.